Drug Trial Radar · NCT05933577
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,089
Planned (sponsor's estimate)
Start
Jul 19, 2023
Primary completion
Oct 26, 2029
Study completion Sep 26, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- ModernaTX, Inc.
- First posted
- Jul 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if intismeran autogene with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
Conditions
- Melanoma
Interventions
Intismeran autogeneBiological
IM injection
PembrolizumabBiological
IV infusion
PlaceboOther
IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence-Free Survival (RFS)Time frame: Up to approximately 74 months
Locations
165 sites in 26 countries. Site status is shown where the registry gives one.
Highlands Oncology Group ( Site 1943)
Springdale, Arkansas
UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1918)
Los Angeles, California
UCSF Medical Center at Mission Bay ( Site 1929)
San Francisco, California
Yale-New Haven Hospital-Yale Cancer Center ( Site 1933)
New Haven, Connecticut
Orlando Health Cancer Institute ( Site 1937)
Orlando, Florida
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 1945)
Tampa, Florida
Winship Cancer Institute of Emory University ( Site 1940)
Atlanta, Georgia
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 1950)
Marietta, Georgia
University of Iowa-Holden Comprehensive Cancer Center ( Site 1935)
Iowa City, Iowa
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Melanoma ( Site 1912)
Baltimore, Maryland
Massachusetts General Hospital ( Site 1927)
Boston, Massachusetts
Beth Israel Deaconess Medical Center ( Site 1957)
Boston, Massachusetts
Dana-Farber Cancer Institute ( Site 1956)
Boston, Massachusetts
University of Michigan ( Site 1915)
Ann Arbor, Michigan
Cancer and Hematology Centers of Western Michigan ( Site 1932)
Grand Rapids, Michigan
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1944)
Hackensack, New Jersey
Atlantic Health System ( Site 1925)
Morristown, New Jersey
Valley Health Systems - Ridgewood Campus ( Site 1947)
Ridgewood, New Jersey
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 1958)
Mineola, New York
NYU Langone Health-Perlmutter Cancer Center ( Site 1917)
New York, New York
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 1908)
New York, New York
Memorial Sloan Kettering Cancer Center ( Site 1914)
New York, New York
University of North Carolina Medical Center-Lineberger Comprehensive Cancer Center ( Site 1949)
Chapel Hill, North Carolina
Duke Cancer Institute ( Site 1911)
Durham, North Carolina
Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 1905)
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center ( Site 1909)
Pittsburgh, Pennsylvania
Medical University of South Carolina-Hollings Cancer Center ( Site 1934)
Charleston, South Carolina
Sanford Cancer Center ( Site 1951)
Sioux Falls, South Dakota
SCRI Oncology Partners ( Site 1910)
Nashville, Tennessee
Texas Oncology - Austin ( Site 1903)
Austin, Texas
Texas Oncology - Dallas (Sammons) ( Site 1902)
Dallas, Texas
University of Texas MD Anderson Cancer Center ( Site 1920)
Houston, Texas
Inova Schar Cancer Institute ( Site 1900)
Fairfax, Virginia
Fred Hutchinson Cancer Center ( Site 1901)
Seattle, Washington
Hospital Aleman ( Site 2200)
Buenos Aires, Argentina
Sanatorio Finochietto ( Site 2205)
Buenos Aires, Argentina
Clinica Adventista Belgrano-Oncology ( Site 2204)
Caba., Buenos Aires, Argentina
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 2202)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Instituto Alexander Fleming-Alexander Fleming ( Site 2203)
Buenos Aires, Buenos Aires F.D., Argentina
Centro Privado de RMI Río Cuarto S.A. II ( Site 2201)
Río Cuarto, Córdoba Province, Argentina
Showing 40 of 165 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.